PMID- 26012738
OWN - NLM
STAT- MEDLINE
DCOM- 20160610
LR  - 20181113
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 5
DP  - 2015 May 27
TI  - Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of 
      knee or hip osteoarthritis.
PG  - 10593
LID - 10.1038/srep10593 [doi]
LID - 10593
AB  - This network meta-analysis aimed to investigate the effectiveness and safety of 
      100 mg BID and 200 mg QD oral celecoxib in the treatment of OA of the knee or 
      hip. PubMed, Embase and Cochrane Library were searched through from inception to 
      August 2014. Bayesian network meta-analysis was used to combine direct and 
      indirect evidences on treatment effectiveness and safety. A total of 24 RCTs 
      covering 11696 patients were included. For the comparison in between the two 
      dosage regimens, 100 mg BID oral celecoxib exhibited a greater probability to be 
      the preferred one either in terms of pain intensity or function at the last 
      follow-up time point. For total gastrointestinal (GI) adverse effects (AEs), both 
      of the two dosage regimens demonstrated a higher incidence compared to the 
      placebo group. Further analyses of GI AEs revealed that only 200 mg QD was 
      associated with a significantly higher risk of abdominal pain when compared with 
      placebo. Furthermore, 100 mg BID showed a significantly lower incidence of skin 
      AEs when compared with 200 mg QD and placebo. Maybe 100 mg BID should be 
      considered as the preferred dosage regimen in the treatment of knee or hip OA.
FAU - Zeng, Chao
AU  - Zeng C
AD  - Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, 
      Hunan Province, China, 410008.
FAU - Wei, Jie
AU  - Wei J
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Central South University, Changsha, Hunan Province, China, 410008.
FAU - Li, Hui
AU  - Li H
AD  - Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, 
      Hunan Province, China, 410008.
FAU - Yang, Tuo
AU  - Yang T
AD  - Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, 
      Hunan Province, China, 410008.
FAU - Gao, Shu-guang
AU  - Gao SG
AD  - Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, 
      Hunan Province, China, 410008.
FAU - Li, Yu-sheng
AU  - Li YS
AD  - Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, 
      Hunan Province, China, 410008.
FAU - Xiong, Yi-Lin
AU  - Xiong YL
AD  - Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, 
      Hunan Province, China, 410008.
FAU - Xiao, Wen-feng
AU  - Xiao WF
AD  - Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, 
      Hunan Province, China, 410008.
FAU - Luo, Wei
AU  - Luo W
AD  - Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, 
      Hunan Province, China, 410008.
FAU - Yang, Tu-bao
AU  - Yang TB
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Central South University, Changsha, Hunan Province, China, 410008.
FAU - Lei, Guang-hua
AU  - Lei GH
AD  - Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, 
      Hunan Province, China, 410008.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20150527
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Dosage Forms)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - Administration, Oral
MH  - Celecoxib/adverse effects/*therapeutic use
MH  - Cyclooxygenase 2 Inhibitors/adverse effects/*therapeutic use
MH  - Databases, Factual
MH  - Dosage Forms
MH  - Gastrointestinal Diseases/etiology
MH  - Humans
MH  - Joints/physiology
MH  - Odds Ratio
MH  - Osteoarthritis, Hip/*drug therapy
MH  - Osteoarthritis, Knee/*drug therapy
MH  - Placebo Effect
MH  - Treatment Outcome
PMC - PMC4445037
EDAT- 2015/05/28 06:00
MHDA- 2016/06/11 06:00
PMCR- 2015/05/27
CRDT- 2015/05/28 06:00
PHST- 2015/01/29 00:00 [received]
PHST- 2015/04/21 00:00 [accepted]
PHST- 2015/05/28 06:00 [entrez]
PHST- 2015/05/28 06:00 [pubmed]
PHST- 2016/06/11 06:00 [medline]
PHST- 2015/05/27 00:00 [pmc-release]
AID - srep10593 [pii]
AID - 10.1038/srep10593 [doi]
PST - epublish
SO  - Sci Rep. 2015 May 27;5:10593. doi: 10.1038/srep10593.